Ovarian Cancer

  • M. Markman


Ovarian cancer is the leading cause of death from female gynecologic malignancies in the United States, exceeding the death rate from cancers of the endometrium and cervix combined. There are approximately 27,000 new cases of ovarian cancer in the United States each year and 15,000 deaths. It has been estimated that a woman has a lifetime risk of developing ovarian cancer of approximately 1 in 70 [1,2]. 567


Ovarian Cancer Clin Oncol Epithelial Ovarian Cancer Advanced Ovarian Cancer Gynecologic Oncology Group 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Parazzini F, Franceschi S, La Vechia C et al (1991) The epidemiology of ovarian cancer. Gynecol Oncol 43:9–23PubMedCrossRefGoogle Scholar
  2. 2.
    Cannistra SA (1993) Cancer of the ovary. N Engl J Med 329: 1550–1558PubMedCrossRefGoogle Scholar
  3. 3.
    Stratton JF, Gayther SA, Russell P et al (1997) Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med 336: 1125–1130PubMedCrossRefGoogle Scholar
  4. 4.
    Carlson KJ, Skates SJ, Singer DE (1994) Screening for ovarian cancer. Ann Intern Med 121:124–132PubMedGoogle Scholar
  5. 5.
    Schapira MM, Matchar DB, Young MJ (1993) The effectiveness of ovarian cancer screening. A decision analysis model. Ann Intern Med 118:838–843PubMedGoogle Scholar
  6. 6.
    Rustin GJS, Nelstrop AE, McClean P et al (1996) Defining response of ovarian carcinoma to initial chemotherapy according to serum CA-125. J Clin Oncol 14:1545–1551PubMedGoogle Scholar
  7. 7.
    Munoz KA, Harlan LC, Trimble EL (1997) Patterns of care for women with ovarian cancer in the United States. J Clin Oncol 15:3408–3415PubMedGoogle Scholar
  8. 8.
    McGuire WP, Hoskins WJ, Brady MF et al (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1–6PubMedCrossRefGoogle Scholar
  9. 9.
    Piccart MJ, Bertelsen K, James K et al (2000) Randomized intergroup trial of cisplatin-paclitaxel versus cisplatincyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst 92: 699–708PubMedCrossRefGoogle Scholar
  10. 10.
    Neijt JP, Engelholm SA, Tuxen MK et al (2000) Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol 18: 3084–3092PubMedGoogle Scholar
  11. 11.
    Ozols RF, Bundy BN, Fowler J et al (1999) Randomized phase III study of cisplatin (CIS)/paclitaxel (PAC) versus carboplatin (CARBO)/PAC in optimal stage III epithelial ovarian cancer (OC): a Gynecologic Oncology Group Trial (GOG 158) (abstract). Proc ASCO 18:356AGoogle Scholar
  12. 12.
    Du Bois A, Lueck HJ, Meier W et al (1999) Cisplatin/paclitaxel vs carboplatin/paclitaxel in ovarian cancer: update of an Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group trial (abstract). Proc ASCO 18:356AGoogle Scholar
  13. 13.
    Alberts DS, Liu PY, Hannigan EV et al (1996) Intraperitoenal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 335:1950–1955PubMedCrossRefGoogle Scholar
  14. 14.
    Markman M, Bundy BN, Alberts DS et al (2001) Phase III trial of standard dose intravenous cisplatin plus paclitaxel versus moderately high dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 19: 1001–1007PubMedGoogle Scholar
  15. 15.
    Omura GA, Bundy BN, Berek JS et al (1989) Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 7:457–465PubMedGoogle Scholar
  16. 16.
    McGuire WP, Hoskins WJ, Brady MF et al (1995) Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 13:1589–1599PubMedGoogle Scholar
  17. 17.
    Gore ME, Mainwaring PN, Macfarlane V et al (1996) A randomized study of high-versus standard-dose carboplatin in patients witih advanced epithelial ovarian cancer (abstract). Proc ASCO 15:284AGoogle Scholar
  18. 18.
    Markman M, Bookman MA (2000) Second-line treatment of ovarian cancer. Oncologist 5:26–35PubMedCrossRefGoogle Scholar
  19. 19.
    Markman M, Rothman R, Hakes T et al (1991) Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:389–393PubMedGoogle Scholar
  20. 20.
    Ten Bokkel Huinink W, Gore M, Carmichael J et al (1997) Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. J Clin Oncol 15:2183–2193PubMedGoogle Scholar
  21. 21.
    Hoskins PJ, Swenerton KD (1994) Oral etoposide is active against platinum-resistant epithelial ovarian cancer. J Clin Oncol 12:60–63PubMedGoogle Scholar
  22. 22.
    Muggia FM, Hainsworth JD, Jeffers S et al (1997) Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. J Clin Oncol 15:987–993PubMedGoogle Scholar
  23. 23.
    Lund B, Hansen OP, Theilade K et al (1994) Phase II study of gemcitabine (2′, 2′-difluorodeoxycytidine) in previously treated ovarian cancer patients. J Natl Cancer Inst 86:1530–1533PubMedCrossRefGoogle Scholar
  24. 24.
    Burger RA, Burman S, White R et al (1996) Phase II trial of navelbine in advanced epithelial ovarian cancer (abstract). Proc ASCO 15:286AGoogle Scholar
  25. 25.
    Markman M, Hakes T, Reichman B et al (1991) Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant disease. J Clin Oncol 10:243–248Google Scholar
  26. 26.
    Francis P, Schneider J, Hann L et al (1994) Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 12:2301–2308PubMedGoogle Scholar
  27. 27.
    Fennelly D, Aghajanian C, Shapiro F et al (1997) Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J Clin Oncol 15: 187–192PubMedGoogle Scholar
  28. 28.
    Markman M, Iseminger KA, Hatch KD et al (1996) Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report. Gynecol Oncol 62:4–6PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • M. Markman

There are no affiliations available

Personalised recommendations